Support The Moscow Times!

Pharmstandard Sales Up

Despite regulatory tightening, drugmaker Pharmstandard posted a 14.7 percent year-on-year rise in second-quarter sales Thursday, reversing a 33 percent decline the previous quarter.

Pharmstandard's revenue amounted to 8 billion rubles ($244.16 million) in the April-through-June period, against 6.98 billion in the same period last year, the company said.

The growth comes despite a change in regulation of sales of codeine-containing medication, which led to a 54 percent drop in revenue from such products compared with the year earlier. The Russian government banned nonprescription sales of pain relievers containing codeine. First-half sales were still down 13.3 percent from a year ago to 16.2 billion rubles, mainly due to weaker sales of anti-flu drugs in the first quarter.

(Reuters)

Read more

Independent journalism isn’t dead. You can help keep it alive.

The Moscow Times’ team of journalists has been first with the big stories on the coronavirus crisis in Russia since day one. Our exclusives and on-the-ground reporting are being read and shared by many high-profile journalists.

We wouldn’t be able to produce this crucial journalism without the support of our loyal readers. Please consider making a donation to The Moscow Times to help us continue covering this historic time in the world’s largest country.